Is COYA or CPRX more undervalued in 2026?

CirclFi compares Coya Therapeutics, Inc. (COYA) and Catalyst Pharmaceuticals, Inc. (CPRX) using 13 institutional-grade valuation models. COYA has a Quality of Company score of 5.5/10 while CPRX scores 10.0/10.

Which is a better buy — COYA or CPRX?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do COYA and CPRX valuations compare?

COYA at $4.83 and CPRX at $31.29 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

COYA vs CPRX Valuation Comparison 2026 — Intrinsic Value Analysis

COYA

Biotechnology

Coya Therapeutics, Inc.

Quality

5.5

out of 10

Value Trap

LOW

Price

$4.83

Last close

Models

9/13

Active

CPRX

Biotechnology

Catalyst Pharmaceuticals, Inc.

Quality

10.0

out of 10

Value Trap

SAFE

Price

$31.29

Last close

Models

13/13

Active

Model-by-Model Comparison

Model	Type	COYA Fair Value	COYA Upside	CPRX Fair Value	CPRX Upside
Bayesian DCF	Intrinsic	$2.48	-48.7%	$31.62	+1.1%
Earnings Power Value	Intrinsic	—	—	$18.57	-40.7%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$0.11	-97.5%	$41.39	+32.3%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for COYA vs CPRX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

COYA vs CPRX — Which Stock Is More Undervalued?

CPRX scores higher with a 10.0/10 quality rating vs COYA's 5.5/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Coya Therapeutics, Inc. (COYA) and Catalyst Pharmaceuticals, Inc. (CPRX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

COYA currently trades at $4.83 with a QOC of 5.5/10, while CPRX trades at $31.29 with a QOC of 10.0/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).